Gender Male
Investor Type
Dr. Frank Yan joined 3E Bioventures Capital as Operating Partner in 2018, and is also the General Manager of N.B. Quadriga, a joint venture biotechnology company discovering and developing innovative drugs for oncology.
Overview
Partner Investments
Announced Date | Organization Name | Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|---|---|
 Myrobalan Therapeutics |  3E Bioventures | Series A - Myrobalan Therapeutics | |||
 Cullgen | 3E Bioventures | Series B - Cullgen | |||
 Regenacy Pharmaceuticals | 3E Bioventures | Series A - Regenacy Pharmaceuticals |
Board and Advisor Roles
- Larkspur Biosciences
Board Member
Recent News and Activity
There is no recent news or activity for this profile.
